Group 1: Industry Insights - Multiple innovative pharmaceutical companies have received significant attention from both domestic and foreign institutional investors, with BeiGene receiving inquiries from 88 institutions and Zai Lab from 36 institutions [1] - The Chinese pharmaceutical industry is entering a critical phase characterized by "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - By 2026, opportunities in innovative commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions are expected to emerge [1] Group 2: Market Performance - As of November 24, 2025, the CSI Hong Kong Innovative Drug Index rose by 3.05%, with the Hong Kong Innovative Drug ETF (513120) increasing by 2.23% and achieving a trading volume exceeding 4.7 billion [2] - Over the past six months, the Hong Kong Innovative Drug ETF has accumulated a return of 33.71% [2] - The latest scale of the Hong Kong Innovative Drug ETF reached 24.102 billion, with continuous net inflows over the past six days totaling 170 million [2] Group 3: Company Developments - Traditional pharmaceutical companies like Heng Rui Medicine and Hansoh Pharmaceutical have successfully completed their innovation transformations, while companies like Bai Li Tianheng have emerged with globally innovative products [1] - Chinese pharmaceutical companies are becoming significant sources of innovation for multinational pharmaceutical firms, with improvements in their global competitiveness [1]

每经AI快讯，11月21日，中国证监会国际合作司发布《关于迈威(上海)生物科技股份有限公司境外发行 上市备案通知书》。迈威生物(688062.SH)拟发行不超过62,664,600股境外上市普通股并在香港联合交易 所上市。该公司曾于2025年1月6日及2025年8月29日向港交所提交上市申请，中信证券和海通国际为其 联席保荐人。 （文章来源：每日经济新闻） ...

Group 1 - The core point of the news is that Maiwei Biotech plans to issue up to 62,664,600 overseas listed ordinary shares and list on the Hong Kong Stock Exchange, with the China Securities Regulatory Commission issuing a notification for the overseas listing registration [1] - Maiwei Biotech focuses on the development of drugs for tumors and age-related diseases, with a competitive and multi-tiered product pipeline that includes over 10 drug assets across various fields such as immunology, ophthalmology, and orthopedics [3] - In the third quarter of 2025, Maiwei Biotech reported a revenue of 465 million yuan, representing a year-on-year increase of 1717.41%, while the net profit attributable to shareholders was a loss of 46.34 million yuan [3] Group 2 - For the first three quarters of 2025, the company achieved a revenue of 565 million yuan, showing a year-on-year growth of 301.03%, but reported a net loss of 598 million yuan attributable to shareholders [3]

智通财经APP获悉，11月21日，中国证监会国际合作司发布《关于迈威(上海)生物科技股份有限公司境外发行上市备案通知书》。迈威生物(688062.SH)拟发 行不超过62,664,600股境外上市普通股并在香港联合交易所上市。该公司曾于2025年1月6日及2025年8月29日向港交所提交上市申请，中信证券和海通国际为 其联席保荐人。 据招股书，迈威生物是一家主要专注于自主开发肿瘤和年龄相关疾病药物并处于商业化阶段的制药公司。多年来，公司建立了具有竞争力的、多层次的管线 产品组合，包括10个以上的药物资产且覆盖不同品种，专注于肿瘤和年龄相关疾病，如免疫、眼科、骨科等领域。 迈威生物2025年第三季度报告显示，前三季度实现营业收入5.65亿元，同比增长301.03%；归属于上市公司股东的净利润为亏损5.98亿元。第三季度实现营 业收入4.65亿元，同比增长1717.41%；归属于上市公司股东的净利润为亏损4634.11万元。 ...

张俊杰表示：此前围绕他婚姻和创业的诸多谣言，让其本人及家人受到了很大伤害，"有必要站出来说话"。 整理 ｜娃娃菜 点击上方【36氪随声听】，一键收听大公司热门新闻。听完音频记得添加进入 【我的小程序】 中哟！ 霸王茶姬创始人发朋友圈辟谣 日前霸王茶姬创始人张俊杰本人通过朋友圈证实了婚讯，并透露已于今年6月登记领证。在感谢公众祝福的同时，张俊杰也表示：此前围绕他婚姻和创业 的诸多谣言，让其本人及家人受到了很大伤害，"有必要站出来说话"。"我郑重声明：在我遇见我妻子（高海纯）前，从未有过婚姻，也从未发生'茶叶富 商残疾女儿'的任何故事。"（新浪财经） 俞敏洪再发全员信道歉，回应被叫老登 11月22日深夜，俞敏洪再发全员全员信再向员工道歉，并详细解释了自己写信的缘由和初衷。对于"用员工的血汗钱旅游"的说法，俞敏洪认为这样的表达 不妥，你在努力工作的同时，老板们也在拼命努力，并承担更大的风险，确保公司的正常发展。 此外，俞敏洪还表示尽管被叫"老登"，自己还是要说几句： 尽管有些人骂我老登，但有关工作和成长的事情，我还是要啰嗦几句。如果你在新东方工作，并且没有放弃这份工作，我觉得你就有责任维护新东方的发 展和形象。如果 ...

今日热点导览 TOP3大新闻 西贝降价，幅度在5%—20%不等 11月22日，根据此前西贝回应公告中的信息，记者前往西贝南京砂之船店探访。当日西贝门店首日开 业，晚高峰就餐人流旺盛，出现明显排队情况。店长向记者介绍，近期西贝全国门店产品降价调改，门 店近40道产品降价，幅度在5%—20%不等。服务员向记者证实此前媒体报道的西贝全员平均涨薪500元 情况属实。（现代快报） 霸王茶姬创始人发朋友圈辟谣 日前霸王茶姬创始人张俊杰本人通过朋友圈证实了婚讯，并透露已于今年6月登记领证。在感谢公众祝 福的同时，张俊杰也表示：此前围绕他婚姻和创业的诸多谣言，让其本人及家人受到了很大伤害，"有 必要站出来说话"。"我郑重声明：在我遇见我妻子（高海纯）前，从未有过婚姻，也从未发生'茶叶富 商残疾女儿'的任何故事。"（新浪财经） 俞敏洪再发全员信道歉，回应被叫老登 11月22日深夜，俞敏洪再发全员全员信再向员工道歉，并详细解释了自己写信的缘由和初衷。对于"用 员工的血汗钱旅游"的说法，俞敏洪认为这样的表达不妥，你在努力工作的同时，老板们也在拼命努 力，并承担更大的风险，确保公司的正常发展。 此外，俞敏洪还表示尽管被叫"老登"，自 ...

Core Viewpoint - The Chinese innovative drug sector is at a critical turning point, transitioning from a "research investment phase" to a "commercial harvest phase," indicating significant long-term growth potential [1][2][3] Group 1: Market Performance - The Dongcai Innovative Drug Index has increased by over 32% year-to-date as of November 20 [1] - The sector experienced a strong rally in the first half of the year, followed by a notable decline [1] Group 2: Institutional Interest - Numerous innovative drug companies, including BeiGene, have attracted intensive research from both domestic and foreign institutions, signaling heightened market interest [1] - BeiGene was researched by 88 public and foreign institutions, while Zai Lab received attention from 36 institutions [1] Group 3: Growth Potential - The sales revenue of domestic innovative drugs is growing rapidly but currently accounts for only about 10% of the overall domestic pharmaceutical market, suggesting over three times potential growth [2] - The next three years are expected to see a significant commercial breakthrough for Chinese innovative drugs in overseas markets, positively impacting the performance of these companies [2] Group 4: R&D and Policy Support - Chinese innovative drug companies have significantly improved their R&D capabilities and gained international recognition, now ranking among the top tier globally in terms of R&D pipeline [2] - Continuous policy support and improvements in commercial insurance payment methods are anticipated to provide additional support for the innovative drug sector [2] Group 5: Investment Opportunities - The Chinese innovative drug industry is perceived to be entering a "historic" investment opportunity phase, with a clear logic chain from scientific breakthroughs to commercialization [3] - As the industry transitions to the "commercial harvest phase," the commercial value of the innovative drug sector is expected to continue to be released, enhancing its growth logic and investment value [3]

Group 1 - The China Securities Regulatory Commission (CSRC) disclosed that two companies have recently obtained approval for overseas issuance and listing [1] - The companies are Maiwei (Shanghai) Biotechnology Co., Ltd. and Shenzhen Zhaowei Electromechanical Co., Ltd. [1] - Maiwei Biotechnology plans to issue no more than 62,664,600 overseas listed ordinary shares and list on the Hong Kong Stock Exchange [1] - Zhaowei Electromechanical plans to issue no more than 69,058,450 overseas listed ordinary shares and also list on the Hong Kong Stock Exchange [1]

Macro Dynamics - The National Internet Information Office and the Ministry of Public Security have released a draft for public consultation regarding the "Regulations on Personal Information Protection for Large Internet Platforms," which mandates that personal information collected within China must be stored domestically [2][3] - The draft encourages large internet platform service providers to innovate in technologies, products, and services related to personal information protection and to participate in the formulation of international standards and rules for personal information protection [3] Market Data - The Nasdaq Composite Index rose by 0.88% on November 21, with major tech stocks showing mixed results; Oracle fell over 5%, while Google and Intel rose over 3% and 2% respectively [11] - The Nasdaq China Golden Dragon Index increased by 1.23%, with notable gains from NIO, Bilibili, and Li Auto [12] Company Dynamics - China Energy Construction Group has appointed Ni Zhen as the new Party Secretary and Chairman, replacing his previous role as General Manager [13] - Jiangsu Railway Group has appointed Ma Tengfei as the new Party Secretary and Chairman, marking a significant leadership change [14][15] - Meituan announced the establishment of "Rider Apartments" nationwide, providing rental subsidies to riders to ensure their rent remains below market levels [16] - Shenzhen Zhaowei Electromechanical Co., Ltd. and Maiwei (Shanghai) Biotechnology Co., Ltd. have received approval from the China Securities Regulatory Commission for their IPOs in Hong Kong [17]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued approval for Shenzhen Zhaowei Electromechanical Co., Ltd. and Maiwei (Shanghai) Biotechnology Co., Ltd. to proceed with their overseas listing plans in Hong Kong [1] Group 1: Company Details - Zhaowei Electromechanical plans to issue no more than 69,058,450 ordinary shares for its overseas listing [1] - Maiwei Biotechnology intends to issue no more than 62,664,600 ordinary shares for its overseas listing [1] Group 2: Market Context - Both companies will be listed on the Hong Kong Stock Exchange, indicating a trend of Chinese companies seeking international capital markets for growth [1]